
Eduard Sergienko, Ph.D.
Eduard Sergienko's Research Focus
Dr. Sergienko has over 20 years of experience, which ranges from basic discovery to translational research. His primary field of expertise is in enzymology, protein chemistry, assay development and chemical biology. Eduard has an established track record of developing cell-based and biochemical assays. He applies his expertise in quantitative biology to designing biologically-relevant assays and devising optimal conditions for identification of small-molecule compounds with desired biological properties.
Dr. Sergienko has established collaborations with Principal Investigators within and outside Sanford Burnham Prebys, which has resulted in drug discovery and chemical biology projects in diverse therapeutic areas. Many of these collaborations attract funding through peer-reviewed mechanisms from NIH centers and institutes and diverse Disease Foundations. Similarly, during the Prebys Center’s participation as one of the four comprehensive centers within NIH Roadmap Initiative Molecule Library Probe production Center Network (MLPCN, and MLSCN prior to this), Eduard collaborated with and helped hundreds investigators within US and around the world with translating their unique biological discoveries and know-how into quantifiable detection properties applicable to lead identification and chemical biology. Eduard’s contributions to the fundamental and applied science (i.e. small molecule drug discovery and chemical biology) comprise 52 publications and 42 book chapters, 34 of which are “NIH Probe Reports” from the Molecular Libraries and 8 chapters are on assay development principles and techniques. Of note, 35 peer-reviewed publications resulted directly from collaborations.
Eduard Sergienko's Bio
Prior to joining Sanford Burnham Prebys Eduard Sergienko was at Triad Therapeutics Inc., a company pioneering NMR- and enzymology-guided fragment-based drug discovery approaches. Starting in 2001, Eduard served as Enzymology group leader and member of several drug discovery project teams. The work of his group was instrumental in identification, optimization and characterization of a preclinical candidate acquired by Novartis Pharma AG (Switzerland) for advancing into clinical trials.
Eduard has over 20 years of experience in the field of biochemistry, with an emphasis on assay design and mechanistic enzymology. He graduated and received his Ph.D. in Biochemistry from the Lomonosov Moscow University (Russia), where his doctoral thesis focused on the role of posttranslational modifications in the regulation of glycolytic enzymes. He furthered his expertise through training as a post-doctoral fellow at Henry Poincare University, France, and Rutgers University, New Jersey focusing on mechanistic enzymology, enzyme kinetics and assay design and development.

Publications
High-throughput screening of tissue-nonspecific alkaline phosphatase for identification of effectors with diverse modes of action.
Sergienko EA, Millán JL
Nat Protoc 2010 Aug ;5(8):1431-9
Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action.
Sergienko E, Su Y, Chan X, Brown B, Hurder A, Narisawa S, Millán JL
J Biomol Screen 2009 Aug ;14(7):824-37
New model for activation of yeast pyruvate decarboxylase by substrate consistent with the alternating sites mechanism: demonstration of the existence of two active forms of the enzyme.
Sergienko EA, Jordan F
Biochemistry 2002 Mar 26 ;41(12):3952-67
Mechanism of Action and Structure-Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor.
Dengler DG, Harikumar KG, Yen A, Sergienko EA, Miller LJ
Membranes (Basel) 2023 Jan 24 ;13(2)
Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity.
Dengler DG, Sun Q, Harikumar KG, Miller LJ, Sergienko EA
SLAS Discov 2022 Oct ;27(7):384-394
Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
Harikumar KG, Coudrat T, Desai AJ, Dong M, Dengler DG, Furness SGB, Christopoulos A, Wootten D, Sergienko EA, Sexton PM, Miller LJ
Front Endocrinol (Lausanne) 2021 ;12:789957
Discovery of small molecule positive allosteric modulators of the secretin receptor.
Dengler DG, Harikumar KG, Pollari S, Sun Q, Brown BT, Shinoki-Iwaya A, Ardecky R, Miller LJ, Sergienko EA
Biochem Pharmacol 2021 Mar ;185:114451
Development of a Testing Funnel for Identification of Small-Molecule Modulators Targeting Secretin Receptors.
Dengler DG, Sun Q, Holleran J, Pollari S, Beutel J, Brown BT, Shinoki Iwaya A, Ardecky R, Harikumar KG, Miller LJ, Sergienko EA
SLAS Discov 2021 Jan ;26(1):1-16